Dr. Reddy’s Laboratories has been granted a patent for methods that involve administering compounds to inhibit VISTA and PD-1 pathways alongside TIM-3 and PD-1 pathways. This approach aims to treat disorders by counteracting immunosuppressive signals associated with these pathways, particularly in cancer treatment. GlobalData’s report on Dr. Reddy’s Laboratories gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Dr. Reddy's Laboratories, Cancer treatment biomarkers was a key innovation area identified from patents. Dr. Reddy's Laboratories's grant share as of July 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Cancer treatment using compounds that inhibit immune checkpoints
The granted patent US12064418B2 outlines a method for treating cancer by conjointly administering two compounds to a subject in need of treatment. The claims specify that the first and second compounds can be various pharmaceutical agents, including their pharmaceutically acceptable salts. The patent encompasses a wide range of cancer types that can be targeted with this treatment method, including but not limited to small cell lung cancer, multiple myeloma, ovarian carcinoma, and various forms of leukemia. The claims also detail specific cancer types, such as colon cancer and non-Hodgkin's lymphoma, indicating a focus on both common and rare malignancies.
Additionally, the patent emphasizes the versatility of the treatment method, allowing for the administration of different combinations of compounds tailored to the specific cancer type being treated. The extensive list of cancers covered by the claims includes a variety of solid tumors, hematological malignancies, and other neoplasms, suggesting a broad applicability of the method across diverse oncological conditions. This comprehensive approach may provide new avenues for therapeutic strategies in cancer treatment, potentially improving outcomes for patients with various forms of the disease.
To know more about GlobalData’s detailed insights on Dr. Reddy's Laboratories, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
